Clinical trials: Neuromuscular Disease Patients
- Condition Neuromuscular Disease Patients
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Diabetic Neuropathy, Painful
Study to Evaluate MK-6096 in the Treatment of Painful Diabetic Neuropathy (PDN) in Adults (MK-6096-021)
The purpose of this study is to evaluate the safety and effectiveness of MK-6096 in the treatment of painful diabetic neuropathy (PDN) in adults.
- Trial name
- NCT01564459
- Testing
- MK-6096
- Volunteers
- 170 people
- Sponsor
- Merck Sharp & Dohme LLC
Pain, Peripheral Neuropathy
A Study to Determine the Maintenance of Effect After Long-term Treatment of Sativex® in Subjects With Neuropathic Pain
The purpose of this study is to assess the maintenance of effect after long-term treatment of Sativex® in subjects with neuropathic pain.
- Trial name
- NCT00713817
- Testing
- Sativex®
- Where
- United Kingdom
- Volunteers
- 19 people
- Sponsor
- Jazz Pharmaceuticals
Centronuclear Myopathy
Early Phase Human Drug Trial to Investigate Dynamin 101 (DYN101) in Patients ≥ 16 Years With Centronuclear Myopathies
There are no available treatments aside from supportive care for patients with Centronuclear myopathy (CNM). This trial will assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD)/preliminary efficacy of…
- Trial name
- Unite-CNM (NCT04033159)
- Testing
- DYN101
- Where
- 8 sites in Belgium, Denmark and 4 more
- Volunteers
- 14 people
- Sponsor
- Dynacure
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Efficacy and Safety Study of I10E in Treatment of Patients With CIDP
Primary objective: To assess the efficacy of I10E in improving the disability of patients with CIDP. Secondary objective: To assess the safety of I10E in patients with CIDP.
- Trial name
- PRISM (NCT02293460)
- Testing
- I10E
- Where
- 33 sites in France, Italy and 4 more
- Volunteers
- 44 people
- Sponsor
- Laboratoire français de Fractionnement et de Biotechnologies
Duchenne Muscular Dystrophy
Efficacy and Safety Study of WVE-210201 (Suvodirsen) With Open-label Extension in Ambulatory Patients With Duchenne Muscular Dystrophy
This is a Phase 2/3, multicenter, randomized, double-blind, placebo-controlled study with an open-label extension period to evaluate the safety and efficacy of WVE-210201 (suvodirsen) in ambulatory male pediatric patients with…
- Trial name
- DYSTANCE 51 (NCT03907072)
- Testing
- WVE-210201 (suvodirsen)
- Where
- 22 sites in United States, Belgium and 6 more
- Volunteers
- 6 people
- Sponsor
- Wave Life Sciences USA, Inc.
Fibromyalgia
A Phase 3 Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With Fibromyalgia
This is a Phase 3, randomized, parallel-group, double-blind, placebo-controlled, 14-week study designed to evaluate the efficacy and safety of TNX-102 SL 5.6 mg (2 x 2.8 mg tablets) taken daily at bedtime for the treatment of…
- Trial name
- RALLY (NCT04508621)
- Testing
- TNX-102 SL
- Where
- 36 sites in United States
- Volunteers
- 514 people
- Sponsor
- Tonix Pharmaceuticals, Inc.
Iron Deficiency, Fibromyalgia
Blinded Randomized Placebo-Controlled Study Efficacy and Safety of Injectafer in ID Patients With Fibromyalgia
This study investigates the efficacy and safety of an IV iron Injectafer in the treatment of iron deficient patients with fibromyalgia.
- Trial name
- NCT02409459
- Testing
- Injectafer
- Where
- United States
- Volunteers
- 81 people
- Sponsor
- American Regent, Inc.
Neuralgia, Postherpetic
A Study In Patients With Neuropathic Pain From Post-Herpetic Neuralgia (PHN)
The purpose of this study is to determine whether gabapentin enacarbil (XP13512/GSK1838262), hereafter referred to as GEn is effective in the treatment of neuropathic pain associated with post-herpetic neuralgia (PHN).
- Trial name
- NCT00619476
- Testing
- GEn 1200mg/day, GEn 2400mg/day, GEn 3600mg/day
- Where
- 83 sites in United States, Canada
- Volunteers
- 376 people
- Sponsor
- XenoPort, Inc.
Generalized Myasthenia Gravis
Evaluating the Long-Term Safety and Tolerability of Efgartigimod PH20 SC Administered Subcutaneously in Patients With Generalized Myasthenia Gravis
The purpose of this study is to evaluate the long-term safety and tolerability of efgartigimod PH20 SC 1000 mg, and the clinical efficacy, PD, pharmacokinetics (PK), immunogenicity, impact on the quality of life (QoL) of the…
- Trial name
- ADAPTSC+ (NCT04818671)
- Testing
- efgartigimod PH20 SC
- Where
- 47 sites in United States, Belgium and 10 more
- Volunteers
- 184 people
- Sponsor
- argenx
Post Herpetic Neuralgia
Safety And Efficacy Study Of Once Daily Controlled Release Pregabalin In The Treatment Of Patients With Postherpetic Neuralgia
The purpose of the study is to explore the safety and efficacy of a new once a day pregabalin formulation versus placebo for patients with post herpetic neuralgia (Shingles)
- Trial name
- NCT01270828
- Testing
- Pregabalin
- Where
- 146 sites in United States, Bulgaria and 15 more
- Volunteers
- 806 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Severe Spasticity
SISTERS: Spasticity In Stroke Study - Randomized Study
To demonstrate that Intrathecal Baclofen (ITB) Therapy, compared to Best Medical Treatment (BMT), has superior efficacy in the treatment of severe spasticity in adult post-stroke patients with generalized spastic hypertonia who…
- Trial name
- SISTERS (NCT01032239)
- Testing
- intrathecal baclofen
- Where
- 25 sites in United States, Austria and 7 more
- Volunteers
- 61 people
- Sponsor
- MedtronicNeuro
Diabetic Neuropathies, Depressive Disorder, Major
Duloxetine in Patients With Diabetic in Peripheral Neuropathic Pain With or Without Co-morbid Major Depressive Disorder
The primary objective is to evaluate, separately in diabetic polyneuropathic pain (DPNP) patients with and without co-morbid major depressive disorder (MDD), whether duloxetine given as 60 mg to 120 mg once daily (QD) leads to a…
- Trial name
- NCT00844194
- Testing
- Duloxetine 60 mg QD, Duloxetine 30 mg QD, Duloxetine 90 mg QD
- Where
- 25 sites in Germany
- Volunteers
- 108 people
- Sponsor
- Boehringer Ingelheim
Diabetic Peripheral Neuropathy
A Study Of The Analgesic (Pain-Relief) Effects Of Tanezumab In Adult Patients With Diabetic Peripheral Neuropathy
The purpose of this study is to determine the effectiveness and safety of the investigational drug, tanezumab, in adult patients with painful diabetic peripheral neuropathy.
- Trial name
- NCT01087203
- Testing
- Tanezumab
- Where
- 48 sites in United States
- Volunteers
- 73 people
- Sponsor
- Pfizer
Neuropathic Pain
A Study to Investigate the Analgesic Efficacy of AZD2423 Compared With Placebo After 28 Days Treatment in Patients With Painful Diabetic Polyneuropathy
A study to investigate the analgesic efficacy of AZD2423 compared with placebo after 28 days treatment in patients with painful diabetic polyneuropathy.
- Trial name
- NCT01201317
- Testing
- AZD2423
- Where
- 20 sites in United States, Canada
- Volunteers
- 134 people
- Sponsor
- AstraZeneca
Neuralgia, Postherpetic, Diabetic Neuropathy
Neuropathic Pain Syndrome Patient Study (MK-0000-072)
The purpose of this study is to determine the best way to conduct clinical trials in patients with neuropathic pain (nerve pain). This study will see if generic pregabalin has any effect on neuropathic pain.
- Conditions
- Neuralgia, Postherpetic, Diabetic Neuropathy, Painful Small-Fiber Neuropathy, Idiopathic Distal Sensory Polyneuropathy
- Trial name
- NCT00570310
- Testing
- Comparator: pregabalin
- Volunteers
- 104 people
- Sponsor
- Merck Sharp & Dohme LLC
Myotonic Dystrophy 1
Study of Tideglusib in Adolescent and Adult Patients With Myotonic Dystrophy
The purpose of this study is to determine whether Tideglusib is safe and efficacious in the treatment of adolescents and adults with congenital and juvenile-onset Myotonic Dystrophy.
- Trial name
- NCT02858908
- Testing
- Tideglusib
- Where
- United Kingdom
- Volunteers
- 16 people
- Sponsor
- AMO Pharma Limited
Neuralgia,Postherpetic
Safety and Efficacy of Gabapentin in Postherpetic Neuralgia
Gabapentin and pregabalin are treatments for some types of neuropathic pain, including postherpetic neuralgia (PHN). However, these treatments usually need to be taken 3 times a day for effective pain control.
- Trial name
- NCT00636636
- Testing
- Gabapentin Extended Release tablets
- Where
- 39 sites in United States, Argentina and 1 more
- Volunteers
- 452 people
- Sponsor
- Depomed
Generalized Myasthenia Gravis
A Study to Test Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis
The purpose of the MycarinGstudy is to demonstrate the clinical efficacy and to assess safety and tolerability of rozanolixizumab in patients with generalized myasthenia gravis (MG).
- Trial name
- NCT03971422
- Testing
- Rozanolixizumab
- Where
- 112 sites in United States, Belgium and 15 more
- Volunteers
- 200 people
- Sponsor
- UCB Biopharma SRL
Amyotrophic Lateral Sclerosis
Study to Investigate the Efficacy and Safety of FAB122 (Daily Oral Edaravone) in Patients With Amyotrophic Lateral Sclerosis
Multicenter, multinational, double-blind, randomized (2:1), placebo-controlled Phase III study to investigate the efficacy and safety of 100 mg FAB122 once daily as oral formulation in ALS patients.
- Trial name
- ADORE (NCT05178810)
- Testing
- FAB122
- Where
- 38 sites in Belgium, France and 9 more
- Volunteers
- 313 people
- Sponsor
- Ferrer Internacional S.A.
Neuropathy, Diabetic
A Study In Patients With Neuropathic Pain From Diabetic Peripheral Neuropathy (DPN)
The purpose of this study is to determine whether gabapentin enacarbil (XP13512/GSK1838262), hereafter referred to as GEn is effective in the treatment of neuropathic pain associated with diabetic peripheral neuropathy(DPN)
- Trial name
- NCT00643760
- Testing
- GEn 1200mg/day, GEn 2400mg/day, GEn 3600mg/day
- Where
- 90 sites in United States
- Volunteers
- 421 people
- Sponsor
- XenoPort, Inc.